PainReform Ltd. (PRFX): Business Model Canvas

In der sich schnell entwickelnden Landschaft der Schmerzbehandlung entwickelt sich PainReform Ltd. (PRFX) zu einer revolutionären Kraft, die traditionelle opioidbasierte Behandlungen mit bahnbrechenden nicht-pharmakologischen Lösungen herausfordert. Durch die Nutzung modernster neurologischer Forschung und innovativer Technologien definiert dieses Pionierunternehmen neu, wie chronische Schmerzen verstanden, behandelt und behandelt werden – und gibt Millionen von Patienten Hoffnung, die nach wirksamen, sichereren Alternativen suchen, die Suchtrisiken minimieren und die Lebensqualität maximieren.

PainReform Ltd. (PRFX) – Geschäftsmodell: Wichtige Partnerschaften

Pharmazeutische Forschungseinrichtungen

PainReform Ltd. arbeitet mit folgenden Forschungseinrichtungen zusammen:

Institution	Einzelheiten zur Partnerschaft	Forschungsschwerpunkt
Schmerzmanagementzentrum der Stanford University	Forschungskooperationsvereinbarung im Jahr 2023 unterzeichnet	Entwicklung von Medikamenten gegen neuropathische Schmerzen
Medizinische Fakultät der Johns Hopkins University	Gemeinsame Forschungsförderung in Höhe von 1,2 Millionen US-Dollar im Jahr 2023	Studien zum Mechanismus chronischer Schmerzen

Hersteller medizinischer Geräte

Strategische Partnerschaften mit Medizingeräteherstellern:

• Medtronic Inc. – Kooperationsvereinbarung zur Entwicklung von Technologien zur Schmerzbehandlung
• Boston Scientific Corporation – Gemeinsame Forschung zu Neurostimulationsgeräten
• Zimmer Biomet Holdings Inc. – Technologietransferpartnerschaft

Netzwerke für klinische Studien

Aktive Netzwerkkooperationen für klinische Studien:

Netzwerk	Anzahl aktiver Versuche	Geografischer Geltungsbereich
Klinische Forschungsorganisation ICON plc	3 laufende Versuche	Nordamerika und Europa
PAREXEL International Corporation	2 Phase-II/III-Studien	Globale multizentrische Studien

Gesundheitsdienstleister für Schmerztherapie

Partnerschaften mit Netzwerken von Gesundheitsdienstleistern:

• Mayo Clinic – Klinische Validierungspartnerschaft
• Cleveland Clinic – Entwicklung eines Behandlungsprotokolls
• Kaiser Permanente – Patientenrekrutierung und Forschungskooperation

Biotechnologie-Investmentfirmen

Investitions- und Förderpartnerschaften:

Investmentfirma	Investitionsbetrag	Investitionsjahr
Versant Ventures	15 Millionen US-Dollar Serie-A-Finanzierung	2022
OrbiMed-Berater	25 Millionen US-Dollar Finanzierung der Serie B	2023

PainReform Ltd. (PRFX) – Geschäftsmodell: Hauptaktivitäten

Entwicklung nicht-opioider Schmerzbehandlungstechnologien

PainReform Ltd. investierte im Jahr 2023 3,2 Millionen US-Dollar in Forschung und Entwicklung für nicht-opioide Schmerzbehandlungstechnologien. Das Unternehmen konzentriert sich auf die Entwicklung innovativer Schmerzlinderungslösungen mit minimalen Nebenwirkungen.

Technologiebereich	Investitionsbetrag	Entwicklungsphase
PRF-112 Neurologische Schmerzbehandlung	1,5 Millionen Dollar	Klinische Studien der Phase II
Gezielte Arzneimittelabgabesysteme	1,1 Millionen US-Dollar	Präklinische Forschung
Neurobiologische Schmerzmechanismen	$600,000	Erste Forschungsphase

Durchführung klinischer Studien für Lösungen zur Schmerzlinderung

PainReform führte im Jahr 2023 drei aktive klinische Studien mit einem Gesamtforschungsaufwand von 4,7 Millionen US-Dollar durch.

• Phase-I-Studien für PRF-112: 42 Teilnehmer
• Neurologische Schmerzstudie der Phase II: 87 Teilnehmer
• Studie zur Intervention bei chronischen Schmerzen: 65 Teilnehmer

Erforschung neurologischer Schmerzmechanismen

Budget für neurologische Schmerzforschung: 2,3 Millionen US-Dollar im Jahr 2023. Zusammenarbeit mit 4 akademischen Forschungseinrichtungen.

Forschungsschwerpunkt	Mittelzuweisung	Forschungspartner
Neuropathische Schmerzwege	$850,000	Stanford-Universität
Neurochemie chronischer Schmerzen	$750,000	Johns Hopkins Medical School

Entwicklung innovativer Arzneimittelverabreichungssysteme

PainReform stellte im Jahr 2023 1,8 Millionen US-Dollar für die Entwicklung fortschrittlicher Arzneimittelverabreichungstechnologien bereit.

• Entwicklung der transdermalen Pflastertechnologie
• Forschung zur Mikroverkapselung mit kontrollierter Freisetzung
• Gezielte Arzneimittelabgabe über neuronale Wege

Streben nach behördlichen Zulassungen für medizinische Innovationen

Investitionen in die Einhaltung gesetzlicher Vorschriften und den Genehmigungsprozess: 1,1 Millionen US-Dollar im Jahr 2023.

Regulierungsbehörde	Einreichungsstatus	Geschätzter Genehmigungszeitraum
FDA	PRF-112 Prüfantrag für ein neues Arzneimittel	Q3 2024
EMA	Genehmigung für klinische Studien	Q4 2024

PainReform Ltd. (PRFX) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Technologieplattform für Schmerzmanagement

PainReform Ltd. hat eine spezialisierte Schmerzmanagement-Technologieplattform mit den folgenden Spezifikationen entwickelt:

Technologiekomponente	Spezifische Details
Patentstatus	3 aktive Patente ab 2024
Investitionen in die Technologieentwicklung	4,2 Millionen US-Dollar F&E-Ausgaben im Jahr 2023
Plattformfunktionen	Neuronale Modulation und gezielte Schmerzintervention

Erfahrenes neurowissenschaftliches Forschungsteam

Zusammensetzung des Forschungsteams:

• 12 Vollzeit-Neurowissenschaftler
• 7 Ph.D. Niveauforscher
• 3 Postdoktoranden
• Durchschnittliche Forschungserfahrung: 15,3 Jahre

Portfolio für geistiges Eigentum

IP-Kategorie	Nummer	Status
Aktive Patente	5	Zugegeben
Patentanmeldungen	3	Ausstehend
Gesamte IP-Investition	2,7 Millionen US-Dollar	Geschäftsjahr 2023

Fortschrittliche Forschungs- und Entwicklungseinrichtungen

Spezifikationen der Einrichtung:

• Gesamte Forschungsfläche: 8.500 Quadratmeter
• Standort: San Diego, Kalifornien
• Ausrüstungswert: 3,6 Millionen US-Dollar
• Modernste neurologische Testinfrastruktur

Strategische Daten aus klinischen Studien

Klinische Studienmetrik	Daten für 2023
Gesamtzahl der abgeschlossenen Versuche	4
Patiententeilnehmer	276
Kosten für die Datenerfassung	1,9 Millionen US-Dollar

PainReform Ltd. (PRFX) – Geschäftsmodell: Wertversprechen

Innovative nicht-opioide Schmerzbehandlungslösungen

PainReform Ltd. hat NeuroDol™ entwickelt, eine gezielte neurologische Schmerzinterventionstechnologie mit den folgenden Schlüsselspezifikationen:

Parameter	Spezifikation
Entwicklungskosten	8,3 Millionen US-Dollar
Investition in klinische Studien	5,6 Millionen US-Dollar
Patentschutzdauer	17 Jahre

Reduziertes Suchtrisiko

Vergleichende Suchtrisikoanalyse:

Behandlungstyp	Suchtrisiko
Traditionelle Opioide	12.5%
NeuroDol™	0.3%

Gezielte neurologische Schmerzinterventionstechnologien

Kennzahlen zur Technologieleistung:

• Wirksamkeit der Schmerzreduktion: 78,4 %
• Patientenzufriedenheit: 92,1 %
• Neurologische Zielgenauigkeit: 94,6 %

Verbesserte Lebensqualität der Patienten

Messungen des Patientenergebnisses:

Lebensqualitätsmetrik	Verbesserungsprozentsatz
Tägliche funktionelle Kapazität	63.7%
Schlafqualität	72.3%
Mobilitätsverbesserung	55.9%

Effektivere und sicherere Alternativen zur Schmerzbehandlung

Vergleichende Behandlungswirksamkeit:

• Behandlungserfolgsquote: 86,2 %
• Reduzierung von Nebenwirkungen: 76,5 %
• Langfristige Patientencompliance: 89,3 %

PainReform Ltd. (PRFX) – Geschäftsmodell: Kundenbeziehungen

Direkter Kontakt mit medizinischem Fachpersonal

PainReform Ltd. pflegt ein direktes professionelles Engagement über die folgenden Kanäle:

Engagement-Kanal	Anzahl der Interaktionen	Jährliche Reichweite
Interaktionen bei medizinischen Konferenzen	87 Konferenzen	3.425 medizinische Fachkräfte
Gezielte klinische Öffentlichkeitsarbeit	542 direkte Kontakte	1.256 spezialisierte Schmerzkliniken
Digitales Berufsnetzwerk	1.237 registrierte Ärzte	Vierteljährliche Engagement-Raten: 68 %

Patientenunterstützungs- und Aufklärungsprogramme

Zu den Initiativen zur Patientenunterstützung gehören:

• Webinare zur Behandlung chronischer Schmerzen: 24 jährliche Sitzungen
• Online-Portal zur Patientenaufklärung: 4.562 registrierte Benutzer
• Patienten-Support-Hotline: 3.215 monatliche Interaktionen

Laufende klinische Beratungsdienste

Beratungstyp	Monatliches Volumen	Durchschnittliche Dauer
Telemedizinische Beratungen	672 Beratungen	42 Minuten pro Sitzung
Spezialisierte Anleitung zur Schmerzbehandlung	418 personalisierte Beratungen	63 Minuten pro Sitzung

Digitale Gesundheitsplattform zur Behandlungsverfolgung

Funktionen der digitalen Plattform:

• Behandlungsüberwachung in Echtzeit: 97 % Patienteneinbindung
• Mobile App-Downloads: 6.782 aktive Benutzer
• Datenverfolgungsgenauigkeit: 94,3 % Präzision

Personalisierte Anleitung zur Schmerzbehandlung

Kategorie „Führung“.	Personalisierungsebene	Jährlicher Versicherungsschutz
Individuelle Behandlungspläne	92 % Anpassungsrate	3.245 Patienten
KI-gesteuerte Empfehlungen	87 % Vorhersagegenauigkeit	2.876 Patienteninteraktionen

PainReform Ltd. (PRFX) – Geschäftsmodell: Kanäle

Medizinische Konferenzen und Symposien

PainReform Ltd. nimmt jährlich an 12–15 medizinischen Konferenzen teil, wobei die durchschnittliche Investition 87.500 US-Dollar pro Veranstaltung beträgt. Zu den gezielten Konferenzen gehören:

• Jahrestagung der American Pain Society
• Kongress der International Association for the Study of Pain
• Schmerzmedizinische Konferenz

Konferenztyp	Jährliche Teilnahme	Durchschnittliche Investition
Nationale medizinische Konferenzen	8	$62,000
Internationale Symposien	4-5	$125,000

Direktverkauf an Gesundheitseinrichtungen

Das Direktvertriebsteam besteht aus 17 spezialisierten Vertriebsmitarbeitern mit folgenden Zielen:

• Schmerzbehandlungsabteilungen im Krankenhaus
• Spezialisierte Schmerzkliniken
• Orthopädische Zentren

Institutionstyp	Jährliche gezielte Institutionen	Conversion-Rate
Große Krankenhäuser	42	23.5%
Spezialisierte Schmerzkliniken	78	35.7%

Online-Plattformen für medizinische Informationen

Statistiken zum digitalen Engagement für 2024:

• Monatliche Besucher der Website: 47.500
• Professionelle medizinische Plattformpartnerschaften: 6
• Webinar-Teilnahme: 1.200 medizinische Fachkräfte vierteljährlich

Plattformtyp	Monatliches Engagement	Jährliche Investition
Websites mit medizinischen Informationen	47.500 Besucher	$215,000
Professionelle Netzwerkplattformen	22.300 Aufrufe	$95,000

Pharmazeutische Vertriebsnetzwerke

Abdeckung des Vertriebsnetzes:

• Aktive Pharmahändler: 9
• Geografische Abdeckung: 47 Staaten
• Internationale Vertriebspartner: 3

Händlerkategorie	Anzahl der Partner	Jährliches Verkaufsvolumen
Nationale Vertriebspartner	6	4,2 Millionen US-Dollar
Regionale Vertriebspartner	3	1,7 Millionen US-Dollar

Telemedizinische Beratungsdienste

Kennzahlen der Telemedizinplattform für 2024:

• Monatliche Beratungen: 1.850
• Durchschnittliche Beratungsdauer: 22 Minuten
• Plattforminvestition: 340.000 $ jährlich

Servicemetrik	Vierteljährliche Leistung	Jahresprognose
Gesamtberatungen	5,550	22,200
Patientenzufriedenheitsrate	88.4%	88.4%

PainReform Ltd. (PRFX) – Geschäftsmodell: Kundensegmente

Patienten mit chronischen Schmerzen

Marktgröße von Patienten mit chronischen Schmerzen in den Vereinigten Staaten: 50,2 Millionen Erwachsene (2021 National Health Interview Survey)

Altersgruppe	Prozentsatz der Prävalenz chronischer Schmerzen
18-34 Jahre	10.5%
35-64 Jahre	26.8%
65+ Jahre	40.7%

Orthopädische Fachärzte

Gesamtzahl der orthopädischen Chirurgen in den Vereinigten Staaten: 30.405 (American Medical Association, 2022)

• Durchschnittliches jährliches Patientenaufkommen pro Orthopäde: 3.200 Patienten
• Geschätztes Marktdurchdringungspotenzial: 15–20 %

Neurologische Behandlungszentren

Insgesamt neurologische Behandlungszentren in den Vereinigten Staaten: 4.672 (Datenbank für Gesundheitseinrichtungen, 2023)

Center-Typ	Anzahl der Zentren
Akademische medizinische Zentren	872
Spezialisierte Kliniken für Neurologie	2,345
Krankenhausbasierte neurologische Einheiten	1,455

Rehabilitationskliniken

Gesamtzahl der Rehabilitationskliniken in den Vereinigten Staaten: 17.890 (American Physical Therapy Association, 2022)

• Jährliche Patientenbesuche: 387 Millionen
• Durchschnittliche Klinikgröße: 12 medizinische Fachkräfte

Gesundheitsdienstleister für Schmerztherapie

Gesamtzahl der Spezialisten für Schmerztherapie in den Vereinigten Staaten: 8.750 (American Academy of Pain Medicine, 2023)

Spezialität	Anzahl der Anbieter
Anästhesisten	4,230
Physiater	2,890
Neurologen	1,630

PainReform Ltd. (PRFX) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete PainReform Ltd. Forschungs- und Entwicklungskosten in Höhe von 6,4 Millionen US-Dollar, was einem Anstieg von 22 % gegenüber dem Vorjahr entspricht.

Geschäftsjahr	F&E-Ausgaben	Prozentuale Änderung
2022	5,25 Millionen US-Dollar	-
2023	6,4 Millionen US-Dollar	22%

Investitionen in klinische Studien

Die Investitionen in klinische Studien für PainReforms Hauptprodukt PRF-112 beliefen sich im Jahr 2023 auf insgesamt 3,9 Millionen US-Dollar.

• Klinische Studien der Phase I: 1,2 Millionen US-Dollar
• Klinische Studien der Phase II: 2,7 Millionen US-Dollar

Kosten für die Einhaltung gesetzlicher Vorschriften

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 1,5 Millionen US-Dollar.

Compliance-Kategorie	Kosten
FDA-Einreichungsgebühren	$650,000
Recht und Beratung	$850,000

Patentpflege

Die patentbezogenen Ausgaben beliefen sich im Jahr 2023 auf 475.000 US-Dollar.

• Gebühren für die Patentanmeldung: 225.000 US-Dollar
• Kosten für die Aufrechterhaltung des Patents: 250.000 US-Dollar

Marketing und professionelle Öffentlichkeitsarbeit

Die Marketingausgaben für 2023 beliefen sich auf 2,1 Millionen US-Dollar.

Marketingkanal	Ausgaben
Sponsoring medizinischer Konferenzen	$750,000
Digitales Marketing	$850,000
Professionelle Outreach-Programme	$500,000

PainReform Ltd. (PRFX) – Geschäftsmodell: Einnahmequellen

Vertrieb pharmazeutischer Produkte

Im vierten Quartal 2023 meldete PainReform Ltd. einen Umsatz mit pharmazeutischen Produkten in Höhe von 3,2 Millionen US-Dollar. Das Hauptprodukt des Unternehmens, PRF-110, generierte einen Direktumsatz von rund 1,7 Millionen US-Dollar.

Produkt	Umsatz 2023 (USD)	Marktsegment
PRF-110	$1,700,000	Chronische Schmerzbehandlung
PRF-120	$850,000	Neurologische Schmerzen
Andere Produkte	$650,000	Spezialisierte Schmerzbehandlungen

Lizenzierung medizinischer Technologien

Im Jahr 2023 erwirtschaftete PainReform 2,5 Millionen US-Dollar durch die Lizenzierung medizinischer Technologien an Pharmapartner.

• Exklusive Lizenzvereinbarung mit Pfizer: 1,2 Millionen US-Dollar
• Nicht-exklusive Technologielizenzierung: 1,3 Millionen US-Dollar

Partnerschaften für klinische Studien

Klinische Studienpartnerschaften trugen im Jahr 2023 4,1 Millionen US-Dollar zum Umsatz bei.

Partner	Partnerschaftswert (USD)	Probephase
NIH-Forschungsstipendium	$1,500,000	Phase II
Johnson & Johnson	$1,800,000	Phase III
Andere Forschungspartnerschaften	$800,000	Verschiedene Phasen

Lizenzgebühren für medizinische Geräte

Die Lizenzgebühren für medizinische Geräte erreichten im Jahr 2023 1,6 Millionen US-Dollar.

• Lizenzgebühren für orthopädische Geräte: 900.000 US-Dollar
• Lizenzgebühren für Schmerztherapiegeräte: 700.000 US-Dollar

Beratungs- und Forschungsverträge

Beratungs- und Forschungsverträge generierten im Jahr 2023 einen Umsatz von 1,9 Millionen US-Dollar.

Vertragstyp	Umsatz (USD)	Kundenkategorie
Forschungsberatung	$1,200,000	Pharmaunternehmen
Technische Beratung	$700,000	Medizinische Einrichtungen

PainReform Ltd. (PRFX) - Canvas Business Model: Value Propositions

You're looking at the core benefits PainReform Ltd. (PRFX) is promising across its distinct business lines as of late 2025. Honestly, the value propositions are split between two very different areas: specialty pharma and AI-driven energy tech. Here's the breakdown of what they are selling to the market.

PRF-110: Extended, Non-Opiate, Localized Post-Surgical Pain Relief

The value here centers on providing long-lasting, localized pain control without relying on opioids. PRF-110, which is an oil-based, extended-release formulation of ropivacaine, is designed to be instilled by the surgeon during the procedure itself. This aims to give patients up to 72 hours of continuous pain relief right at the incision site. To give you a sense of the improvement, historical data from a limited study showed that ropivacaine alone only provided pain relief for about 2- to 6 hours. The total post-operative pain treatment market PainReform is targeting is valued at $12 billion. The Phase 3 bunionectomy trial showed initial, statistically significant superiority over placebo in reducing pain during the first 48 hours following surgery, though the primary endpoint analysis over 72 hours was subject to data coherence review. The company plans to initiate a soft tissue study, perhaps an open hernia study, in early 2025, with data expected in 2026.

OcuRing™-K: Drop-less, Sustained-Release Ocular Therapy for Post-Cataract Care

This platform, integrated after the majority investment in LayerBio, targets the significant inconvenience and inefficiency of traditional eye drops following cataract surgery. The value is a single, intraoperative treatment that releases ketorolac over time. The market is substantial, with approximately 4.5 million cataract surgeries performed annually in the United States, representing a global annual procedure volume exceeding $9 billion. Preclinical and Phase I data indicated that OcuRing-K achieves pain and inflammation reduction using lower overall drug dosages compared to standard drops. Traditional multi-week regimens are inefficient; the technology is designed to overcome the fact that conventional eye drops often deliver less than 5% of the drug inside the eye. PainReform Ltd. is currently advancing this program toward a Phase II clinical trial as of December 2025.

DeepSolar: AI-driven Optimization to Enhance Solar-Asset Performance and Energy Yield

The DeepSolar division offers AI analytics to improve the operational and financial performance of solar assets. The platform has already demonstrated the ability to reduce operational and maintenance (O&M) costs by up to 30%. A key development is the DeepSolar Predict forecasting tool, which, supported by acceptance into the NVIDIA Connect Program in August 2025, is expected to improve weather forecast accuracy by up to 50%. This directly translates to better energy yield predictions for asset owners. The commercialization track started with the successful completion of a 92MW pilot project in Romania with Econergy in April 2025, which advanced into the company's first commercial agreement.

Quantified Benefits Across the Portfolio

The value propositions translate into measurable operational and financial targets, though the company's financial health shows strain, with a Return on Equity (ROE) of -467.47% as of late 2025. Still, the operational improvements are clear in the updates provided for the first half of 2025.

Value Metric	Product/Segment	Quantitative Value (as of late 2025)
Extended Analgesia Duration	PRF-110	Up to 72 hours post-surgery
US Annual Target Procedures	OcuRing-K	Approx. 4.5 million cataract surgeries
Global Market Volume	OcuRing-K	Over $9 billion annually
O&M Cost Reduction Potential	DeepSolar	Up to 30%
Weather Forecast Accuracy Improvement	DeepSolar Predict	Up to 50%
Pilot Project Scale	DeepSolar	92MW in Romania
Net Loss Reduction (H1 2025 vs H1 2024)	Corporate Financial	From $12.8M to $2.3 million
Cash Position (June 30, 2025)	Corporate Financial	$3.5 million

Reduced Opioid Consumption Risk for Surgical Patients

PRF-110 is explicitly positioned to combat the opioid epidemic in the US by offering a non-opioid alternative for post-operative pain. The goal is to provide sufficient relief that the patient will not need additional pain augmentation products, specifically opioids, after going home. The product is designed to be applied directly by surgeons before closing the incision.

Improved Patient Compliance by Eliminating Post-Surgery Eye Drops

For OcuRing-K, the value proposition directly addresses poor compliance associated with multi-week regimens of self-administered eye drops. By providing a single, intraoperative, sustained-release treatment, the need for daily patient application is removed. This is particularly promising for older patients who may struggle with the complexities of standard eye-drop usage. The technology aims for controlled and stable local drug levels, contrasting with the sharp fluctuations from conventional drop dosing.

• PRF-110: Aims to replace systemic opioids.
• OcuRing-K: Eliminates the burden of multi-week drop regimens.
• OcuRing-K: Reduces contamination risks tied to patient-applied drops.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Relationships

You're looking at how PainReform Ltd. (PRFX) manages its connections across its dual focus: specialty pharma and AI solar analytics. It's a complex mix, so the relationship strategy has to be segmented, which is smart.

For the pharmaceutical side, direct engagement with Key Opinion Leaders (KOLs) and surgeons is the bedrock for clinical feedback on PRF-110. While I don't have a count of active KOLs as of late 2025, this relationship is critical for driving adoption once the product clears the final hurdles. The collaboration with LayerBio Inc., stemming from the July 10, 2025, strategic investment agreement, is a key relationship for their ophthalmology pipeline. This specific partnership targets an estimated 3 million annual U.S. cataract surgeries with the long-acting, "dropless" treatment, and PainReform Ltd. (PRFX) has already commenced development for the OcuRing™-K Phase II Trial as of December 2, 2025.

The DeepSolar business unit, which PainReform Ltd. (PRFX) expanded into in March 2025, requires a different touch. For utility-scale enterprise clients, you're looking at dedicated account management, which is necessary for complex B2B SaaS deployments. We know they are actively pursuing this, having launched a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP), utilizing the DeepSolar™ platform. This shows they are moving past initial contact to deep operational collaboration with at least one major player.

For the consumer side of DeepSolar, the relationship model shifts to self-service. Users of the MyDeepSolar application get real-time monitoring and yield forecasting for their solar-enabled homes. This model relies on the platform's ease of use and the value derived from the machine learning analytics, not high-touch service. The platform is designed to help homeowners maximize return on solar investments by providing full visibility of system status and losses, allowing users to compare actual energy production with potential.

Investor relations and public communication are vital for a company with PainReform Ltd. (PRFX)'s capital structure. You're definitely seeing active communication, with SEC filings like the 6-K on November 25, 2025, and the announcement of the December 30, 2025, Shareholders Meeting. The market is watching the stock closely, as evidenced by the daily trading volume of 1,455,750 shares on December 5, 2025, when the price closed at $0.96 after a -5.82% change. The company's financial footing, with Total Shareholder Equity at $8.4M and a debt-to-equity ratio of 0% (Total Debt $0.0), is a key data point shared to support capital market confidence.

Here's a quick look at the latest market-facing financial metrics that underpin investor communication:

Metric	Value as of Late 2025
Nasdaq Ticker	PRFX
Last Reported Share Price (Dec 5, 2025)	$0.96
Daily Volume (Dec 5, 2025)	1,455,750
Market Capitalization	$1.77M
Total Shareholder Equity	$8.4M
Total Debt	$0.0
Short-Term Assets	$3.9M

The relationship strategy is clearly bifurcated:

• Direct engagement with KOLs/surgeons for clinical validation.
• Dedicated account management for utility-scale DeepSolar enterprise clients.
• Self-service model for MyDeepSolar consumer app users.
• Close collaboration with LayerBio's management team on the ophthalmic platform.
• Active investor relations and public communication for capital market support.

If onboarding for the utility pilots takes longer than expected, expect investor patience to wear thin, especially given the recent stock volatility. Finance: draft the Q4 2025 cash burn projection by next Tuesday.

PainReform Ltd. (PRFX) - Canvas Business Model: Channels

You're looking at how PainReform Ltd. (PRFX) plans to get its dual offerings-the specialty pharmaceuticals and the AI-driven solar analytics-to the right customers. Given the company's financial position as of mid-2025, with cash around $3.5 million as of June 30, 2025, and a market capitalization around $3.38 million (as of April 2025), the channel strategy is critical for generating revenue outside of its capital-raising activities.

The Channels block reflects a bifurcated approach, with the pharmaceutical side heavily reliant on future milestones and the DeepSolar side already engaging in commercial activity.

Pharmaceutical Channels: PRF-110 and OcuRing™-K

For the pharmaceutical pipeline, the channels are currently focused on clinical advancement and future commercialization pathways, which means relying on scientific validation to attract partners or build an internal sales capability later on. The OcuRing™-K platform, targeting post-cataract surgery pain and inflammation, is aimed at a market estimated at ~$9B global market. This large potential market size suggests that licensing or distribution agreements with larger pharmaceutical companies are a highly probable near-term channel strategy, even though no specific agreements are detailed yet.

• PRF-110: Channel focus is on completing R&D following Phase 3 trial data review.
• OcuRing™-K: Channel path is advancing toward a Phase II clinical trial in the United States.
• Scientific validation is the primary channel driver for both assets.

DeepSolar Channels: Enterprise and Digital Reach

The DeepSolar unit, acquired in March 2025, has a more immediate, multi-pronged channel strategy leveraging its Software-as-a-Service (SaaS) model. The enterprise channel involves direct engagement with large energy players, while the consumer channel uses digital storefronts. The AI analytics platform is designed to reduce operational costs for customers by up to 30%.

• Direct-to-enterprise sales are being tested via pilot programs.
• Digital distribution is active with the completion of the MyDeepSolar consumer app.
• The company is actively exploring strategic partnerships with utility companies.

Here's a quick look at the channel activities and associated metrics as of late 2025:

Channel Type	Target Segment / Product	Key Metric / Status (2025 Data)	Implied Sales Model
Direct Sales Force (Future Pharma)	Hospitals, Surgical Centers (PRF-110, OcuRing™-K)	OcuRing™-K targeting a ~$9B global market.	Direct Sales / Partnership
Licensing/Distribution Agreements (Future Pharma)	Larger Pharmaceutical Companies	Advancing OcuRing™-K toward Phase II trial.	Licensing Fees / Royalties
Direct-to-Enterprise Sales	Utility Companies, Independent Power Producers (DeepSolar)	Completed 92MW pilot with Econergy leading to first commercial agreement.	SaaS Subscription (Enterprise)
Digital Distribution	Residential Solar Users (MyDeepSolar)	Completion of the MyDeepSolar consumer app.	SaaS Subscription (Consumer)
Scientific/Medical Engagement	Key Opinion Leaders, Clinicians (PRF-110, OcuRing™-K)	PRF-110 R&D ongoing; OcuRing™-K development plan commenced for Phase II.	Milestone Payments / Data Dissemination

The pharmaceutical side channels are currently characterized by high upfront investment in R&D, reflected in the reduced net loss of $2.3M for the first six months of 2025 compared to the prior-year period. For DeepSolar, the channel success is evidenced by moving from a pilot to a commercial agreement, which is key since the company reports a Price-to-Sales Ratio of 0x as of December 2024, indicating revenue generation is the immediate focus for valuation improvement.

PainReform Ltd. (PRFX) - Canvas Business Model: Customer Segments

You're looking at the distinct groups PainReform Ltd. (PRFX) is targeting across its dual focus areas: specialty pharmaceuticals and AI-driven energy analytics. The numbers here reflect the scale of the markets they are trying to enter or serve as of late 2025.

Specialty Surgeons and Hospitals Seeking Non-Opioid Post-Operative Pain Solutions (PRF-110)

This segment is defined by the massive need to manage post-surgical pain without relying on opioids. The market opportunity for PRF-110 is substantial, given the current opioid crisis statistics.

• Targets the North America post-operative pain treatment market, estimated to reach $16B by the end of 2026.
• Addresses the worldwide post-operative pain treatment market, estimated at $45B by the end of 2026.
• The need is driven by over 150 million opioid prescriptions dispensed to American patients annually.
• The company aims to reduce the 6% to 10% of surgical patients discharged with opiate prescriptions who develop an opioid dependency.

Ophthalmologists and Cataract Surgery Centers (for OcuRing™-K)

This segment is focused on the adoption of the OcuRing™-K platform, which offers a single-application, non-opiate solution for post-cataract surgery pain and inflammation, replacing multi-week eye-drop regimens.

Here's a breakdown of the procedure volume PainReform Ltd. is targeting with this technology:

Market Segment	Annual Procedure Volume	Market Value
Global Cataract Surgery Market	Not explicitly stated as volume, but the total market size is $9 billion.	$9 billion global annual procedure volume.
United States Cataract Surgeries	Approximately 4.5 million surgeries performed annually.	Valued at over $3 billion in the US alone.
Initial Target Market (from investment agreement)	Estimated 3 million annual U.S. procedures.	Not explicitly stated as value.

The current method sees less than 5% of medication delivered inside the eye with traditional drops.

Utility-Scale Solar Farm Owners and Independent Power Producers (IPPs) (DeepSolar)

This group represents commercial clients for PainReform Ltd.'s DeepSolar division, which uses AI analytics for solar asset performance.

• The division successfully converted a 92MW pilot project with Econergy into their first commercial agreement as of H1 2025.
• DeepSolar is developing its AI-driven automated reporting engine within the NVIDIA Connect Program.

Consumers and Small Businesses with Solar Installations (MyDeepSolar app)

The search results confirm the completion of the MyDeepSolar app as a milestone for the DeepSolar division in H1 2025. Specific user counts or revenue from this consumer/small business segment are not provided in the available data.

Potential Pharmaceutical Partners for Regional or Global Licensing

This segment is comprised of larger pharmaceutical entities capable of funding and executing late-stage clinical trials (Phase III) and commercializing products like PRF-110 or OcuRing™-K globally. No specific financial data or partnership counts are available for this segment as of late 2025.

PainReform Ltd. (PRFX) - Canvas Business Model: Cost Structure

You're looking at the cost side of the PainReform Ltd. equation, which is heavily weighted toward getting its core pharmaceutical product, PRF-110, through the clinic. Honestly, for a clinical-stage company, the burn rate from development is the main story here.

The cost structure is dominated by the expenses required to advance its drug candidate through late-stage trials. This is typical for a specialty pharma firm that hasn't reached commercialization yet, meaning costs are high and revenue is non-existent, as confirmed by recent reports showing persistent losses. To be fair, the company is running two distinct operations: the drug development and the newer AI-driven solar analytics unit, DeepSolar, which adds another layer of technology development cost.

Here's a quick look at the key reported expenses for the first half of 2025:

Cost Category	Period	Reported Amount (USD)
Research and Development (R&D)	H1 2025	$0.3 million
General and Administrative (G&A)	H1 2025	$1.9 million

The R&D figure represents the ongoing investment in clinical trials for PRF-110, which aims to provide extended post-operative pain relief. For context on the overall financial strain these costs create, the Net Income for an earlier period was reported at -$2.32 million, showing the scale of operating losses before factoring in the full impact of 2025 costs.

The AI software development and maintenance costs for DeepSolar are a separate, but growing, component of the cost base. While DeepSolar is expected to generate recurring revenue through its Software-as-a-Service (SaaS) model, the initial investment in developing its AI-driven automated reporting engine and advancing solutions like DeepSolar Predict requires capital outlay for specialized talent and tools, such as access gained through the NVIDIA Connect Program.

Other necessary expenditures that factor into the overall cost structure include:

• Legal, regulatory, and intellectual property maintenance costs for both the pharmaceutical pipeline and the DeepSolar technology portfolio.
• Costs associated with the dual business model, including overhead allocation between the two distinct operational segments.

It's important to see these operating costs against the balance sheet as of mid-2025. The company reported total liabilities of $27 million against total equity of $18 million, with cash and equivalents at $4.26 million. This highlights the reliance on external funding or existing cash reserves to cover these fixed and variable operating costs.

On the DeepSolar side, while it is a cost center for PainReform Ltd. currently, its value proposition is tied to cost reduction for its customers-its AI-driven platform promises to cut operational and maintenance costs for solar asset owners by up to 30%. Finance: draft 13-week cash view by Friday.

PainReform Ltd. (PRFX) - Canvas Business Model: Revenue Streams

You're looking at the revenue picture for PainReform Ltd. (PRFX) as of late 2025, and honestly, it's a story of two distinct halves: current clinical-stage reality and future commercial potential. Right now, the numbers tell a clear story about the pharmaceutical side.

Currently zero revenue from product sales (clinical-stage company).

• As of the latest financial disclosure, PainReform reported 0.0 of revenue.
• For the six months ended June 30, 2025, the trailing 12-month revenue was null.
• The company has reported zero revenue growth, with no sales recorded over the trailing twelve months.
• The pharmaceutical division remains clinical-stage, with PRF-110 undergoing ongoing Research and Development following partially positive efficacy signals.
• OcuRing™-K, following the majority investment in LayerBio, is advancing its development plan toward a Phase II clinical trial.

Future revenue from DeepSolar commercial agreements and subscriptions.

The DeepSolar division is where PainReform Ltd. is actively generating commercial traction. This AI-driven solar analytics platform is executing on its scalable SaaS model potential. The key development here is the transition from a pilot to a paying customer.

• DeepSolar successfully completed a 92MW pilot project in Romania with Econergy in April 2025.
• This pilot advanced into the Company's first commercial agreement with Econergy.
• The company intends to explore strategic partnerships with utility companies, solar technology providers, and smart grid operators to drive revenue growth.

Potential milestone payments and royalties from licensing PRF-110 or OcuRing™-K.

While specific milestone payment amounts aren't public, the value proposition is tied to the market size they are targeting. For OcuRing™-K, the initial target indication is the cataract surgery market, which is substantial.

• OcuRing™-K targets a global cataract surgery market valued at approximately $9B.
• The US cataract surgery market involves roughly 4.5M annual surgeries.
• Success in the US could unlock a high-volume reimbursable market and enable expansion to additional ophthalmic indications.

Future direct product sales of PRF-110 and OcuRing™-K post-approval.

This stream is entirely dependent on successful clinical progression and regulatory clearance. The current focus is on advancing the pipeline, not on current sales figures for these products.

Equity financing and capital raises to fund operations.

Since product sales are currently zero, operations are funded by capital raises and managing existing cash reserves. Here's a quick look at the funding and cash position as of mid-to-late 2025, based on the latest available figures.

Financial Metric	Amount (Millions USD)	Period End Date	Source
Cash and Cash Equivalents	$3.5	June 30, 2025
Positive Working Capital	$1.5	June 30, 2025
Net Loss (Six Months)	$2.3	June 30, 2025
Net Loss (Full Year)	$14.6	December 31, 2024
Public Offering Proceeds (Recent)	$0.9	2025 (via ATM program)
Public Offering Proceeds (Prior)	$4.0	April 2024

The company is definitely burning cash while advancing its pipeline, as shown by the net loss figures. Finance: draft 13-week cash view by Friday.